TScan Therapeutics (TCRX) Price & Analysis

Compare

251 Followers

TCRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.02 - $6.23

Previous CloseN/A

Volume150.47K

Average Volume (3M)293.29K

Market Cap

$101.86M

Enterprise Value$66.76M

Total Cash (Recent Filing)$218.04M

Total Debt (Recent Filing)$64.40M

Price to Earnings (P/E)―

Beta1.71

Next Earnings

Nov 05, 2025

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding52,314,037

10 Day Avg. Volume207,177

30 Day Avg. Volume293,286

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue9.59

Enterprise Value/Gross Profit10.68

Enterprise Value/Ebitda-0.51

Forecast

1Y Price Target

$7.67

Price Target Upside326.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementTSC-100/101 continued to strongly favor the treatment arm, with a significantly lower relapse rate compared to the control arm.

Financial StabilityThe company ended with $218M, supporting operations into the future.

Regulatory ProgressTCRX remains on track for a meeting with the FDA to discuss details for the pivotal study of TSC-101, with study start still planned.

Bears Say

Clinical ChallengesInitial data for the multiplex solid tumor program has been pushed out, indicating challenges in identifying suitable patients.

Statistical SignificanceThe 23% vs. 58% probability of relapse did not meet statistical significance, likely due to the short duration of follow-up and small patient population.

TScan Therapeutics News

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

Reports Q2 revenue $3.076M, consensus $1.3M. “We expect to dose our first solid tumor patients with multiplex TCR-T...

5d ago

TCRX

TScan Therapeutics expects cash to fund operations into Q1 of 2027

Cash, cash equivalents, and marketable securities as of June 30, 2025, were $218.0 million, excluding $5.0 million of...

5d ago

TCRX

TScan Therapeutics: Promising Developments and Strategic Advancements Drive Buy Rating

BTIG analyst Justin Zelin has maintained their bullish stance on TCRX stock, giving a Buy rating on August...

2d ago

TCRX

Strategic Advancements and Promising Trial Data Propel TScan Therapeutics to ‘Buy’ Rating

H.C. Wainwright analyst Andres Y. Maldonado has reiterated their bullish stance on TCRX stock, giving a Buy rating...

2d ago

TCRX

TScan Therapeutics Reports Q2 2025 Financial Results

Tscan Therapeutics, Inc. ( ($TCRX) ) has released its Q2 earnings. Here is a breakdown of the information...

5d ago

TCRX

TCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Tscan Therapeutics, Inc. (TCRX) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall Street...

7d ago

TCRX

TScan Therapeutics Elects New Directors at Annual Meeting

TScan Therapeutics ( ($TCRX) ) has provided an update. On June 30, 2025, TScan Therapeutics held its annual...

2M ago

TCRX

TScan Therapeutics management to meet virtually with BTIG

Virtual Meeting to be held on May 15 hosted by BTIG. Published first on TheFly – the ultimate...

3M ago

TCRX

TScan Therapeutics price target lowered to $10 from $15 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on TScan Therapeutics (TCRX) to $10 from $15...

3M ago

TCRX

TScan Therapeutics Reports Q1 2025 Financial Results

Tscan Therapeutics, Inc. ( ($TCRX) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

TCRX

Positive Outlook for TScan Therapeutics: Buy Rating Backed by Strong Financials and Promising Clinical Developments

Gil Blum, an analyst from Needham, maintained the Buy rating on TScan Therapeutics (TCRX – Research Report). The...

3M ago

TCRX

TScan Therapeutics reports Q1 EPS (26c), consensus (28c)

Reports Q1 revenue $2.171M, consensus $1.08M. “This is an exciting year for TScan as we advance our mission...

3M ago

TCRX

TScan Therapeutics appoints Camiolo as SVP, Market Access

TScan Therapeutics (TCRX) announced the appointment of Stephen Camiolo as Senior Vice President, SVP, Market Access. Camiolo brings...

5M ago

TCRX

TScan Therapeutics assumed with an Overweight at Morgan Stanley

Morgan Stanley analyst Maxwell Skor assumed coverage of TScan Therapeutics (TCRX) with an Overweight rating and $10 price...

5M ago

TCRX

TCRX FAQ

What was TScan Therapeutics’s price range in the past 12 months?

TScan Therapeutics lowest stock price was $1.02 and its highest was $6.22 in the past 12 months.

What is TScan Therapeutics’s market cap?

TScan Therapeutics’s market cap is $101.86M.

When is TScan Therapeutics’s upcoming earnings report date?

TScan Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 80 days.

How were TScan Therapeutics’s earnings last quarter?

TScan Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.327 by $0.047.

Is TScan Therapeutics overvalued?

According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TScan Therapeutics pay dividends?

TScan Therapeutics does not currently pay dividends.

What is TScan Therapeutics’s EPS estimate?

TScan Therapeutics’s EPS estimate is -0.33.

How many shares outstanding does TScan Therapeutics have?

TScan Therapeutics has 52,314,037 shares outstanding.

What happened to TScan Therapeutics’s price movement after its last earnings report?

TScan Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.327. Following the earnings report the stock price went up 3.727%.

Which hedge fund is a major shareholder of TScan Therapeutics?

Currently, no hedge funds are holding shares in TCRX

TScan Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-63.33%

Trailing 12-Months

Asset Growth

-20.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

TScan Therapeutics

TScan Therapeutics, Inc. (TCRX) is a biotechnology company focused on developing T-cell receptor-engineered T-cell therapies for the treatment of cancer. The company operates within the biotechnology and life sciences sector, leveraging its proprietary technology platform to identify and target cancer-specific antigens. TScan's core products include a pipeline of TCR-T cell therapies aimed at providing innovative and effective treatments for various types of cancer.

TScan Therapeutics (TCRX) Earnings & Revenues

Historic Earnings Reports

TCRX Stock 12 Month Forecast

Average Price Target

$7.67

▲(326.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.418461538461538,3.2169230769230768,4.015384615384615,4.813846153846153,5.6123076923076916,6.4107692307692306,7.209230769230769,8.007692307692306,8.806153846153844,9.604615384615382,10.40307692307692,11.201538461538462,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.0853846153846156,2.550769230769231,3.016153846153846,3.4815384615384617,3.946923076923077,4.412307692307692,4.877692307692308,5.343076923076923,5.808461538461539,6.273846153846154,6.73923076923077,7.204615384615384,{"y":7.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,1.6492307692307693,1.6784615384615384,1.7076923076923078,1.736923076923077,1.7661538461538462,1.7953846153846154,1.8246153846153847,1.853846153846154,1.883076923076923,1.9123076923076923,1.9415384615384617,1.9707692307692308,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.62,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.83,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >